Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + tetrahydrocannabinol (St. Joseph's Healthcare Hamilton)
- Development stage
- Phase 3
- Lead developer
- McMaster University and St. Joseph's Healthcare Hamilton
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
This cannabis-infused oil is an investigational drug product containing a combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) in specific ratios, primarily 25:1 and 5:1. Developed by St. Joseph's Healthcare Hamilton in collaboration with McMaster University, it is being evaluated in a Phase 2 clinical trial (NCT05041647) for the treatment of insomnia in adults with major depressive disorder (MDD). The formulation leverages the therapeutic properties of CBD, a non-intoxicating cannabinoid with potential anxiolytic and sedative effects, and low-dose THC, which may enhance efficacy through the entourage effect. The study aims to assess the safety and efficacy of high-dose (50 mg/mL) versus low-dose (10 mg/mL) CBD concentrations in improving sleep parameters such as sleep latency and wake after sleep onset.
- Brand names
- Avidekel
- Other names
- cannabis-infused oilCBD/THC oil25:1 CBD/THC5:1 CBD/THC
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on cannabidiol + tetrahydrocannabinol (St. Joseph's Healthcare Hamilton).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + tetrahydrocannabinol (St. Joseph's Healthcare Hamilton).